Bisphosphonate Dosing in ESRD Patients

Primary Recommendation: Avoid Bisphosphonates in ESRD

Zoledronic acid is contraindicated when creatinine clearance is less than 35 mL/min due to significantly increased risk of renal failure (32.1% vs 7.7% in placebo for patients with pre-existing moderate renal impairment) 1
The American College of Cardiology is not mentioned, however, it is generally recommended that bisphosphonates are contraindicated in ESRD patients (creatinine clearance <30-35 mL/min), and denosumab is the preferred bone-protective agent in this population due to its lack of renal excretion and superior safety profile 1, 2

Denosumab is the treatment of choice for osteoporosis or bone disease in ESRD patients because it does not require renal dose adjustment or monitoring 1
Denosumab demonstrates fewer adverse renal events compared to bisphosphonates 1
Denosumab has lower renal toxicity due to non-renal metabolism 2
Aggressive calcium monitoring and supplementation is mandatory due to high risk of severe hypocalcemia in dialysis patients 2
Monitor serum calcium, phosphorus, magnesium, and intact PTH regularly 2
Ensure adequate vitamin D levels before initiating therapy 2
Never discontinue denosumab abruptly due to risk of rebound bone resorption 1

Pamidronate 90 mg administered over 4-6 hours (not the standard 2 hours) can be considered if extensive bone disease necessitates bisphosphonate use in severe renal impairment (CrCl <30 mL/min) 1, 2
Consider reducing the initial pamidronate dose in patients with pre-existing renal impairment 3, 1
Never use zoledronic acid in ESRD 1
Never shorten infusion times (pamidronate must be ≥2 hours; zoledronic acid ≥15 minutes if used in less severe CKD) 3, 4, 2
Never increase doses or reduce dosing intervals 3, 4

Before each bisphosphonate dose (if used): serum creatinine 3, serum calcium, electrolytes, phosphate, magnesium 4, hematocrit/hemoglobin 4
Every 3-6 months: albuminuria evaluation 1, withhold bisphosphonates if unexplained albuminuria ≥500 mg/24 hours develops 2
Limit therapy to up to 2 years maximum 1
Consider discontinuation at 2 years in patients with responsive or stable disease 4
Resume only if new skeletal-related events occur on relapse 4